THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 110 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2019. The put-call ratio across all filers is 2.28 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,967,066 | -1.1% | 575,558 | +18.6% | 0.00% | 0.0% |
Q2 2023 | $5,024,046 | -73.9% | 485,415 | -72.7% | 0.00% | -50.0% |
Q1 2023 | $19,269,230 | +95.8% | 1,775,966 | +102.4% | 0.00% | +100.0% |
Q4 2022 | $9,843,026 | +5.4% | 877,275 | -4.8% | 0.00% | 0.0% |
Q3 2022 | $9,342,000 | +52.6% | 921,281 | +36.4% | 0.00% | 0.0% |
Q2 2022 | $6,121,000 | -4.3% | 675,633 | +1.0% | 0.00% | 0.0% |
Q1 2022 | $6,395,000 | +1210.5% | 668,896 | +1412.7% | 0.00% | – |
Q4 2021 | $488,000 | +24.2% | 44,220 | -16.8% | 0.00% | – |
Q3 2021 | $393,000 | -62.2% | 53,139 | -25.8% | 0.00% | – |
Q2 2021 | $1,040,000 | -50.2% | 71,576 | -30.0% | 0.00% | – |
Q1 2021 | $2,087,000 | +43.9% | 102,213 | +25.2% | 0.00% | – |
Q4 2020 | $1,450,000 | +40.9% | 81,634 | +17.4% | 0.00% | – |
Q3 2020 | $1,029,000 | -46.6% | 69,564 | -24.3% | 0.00% | – |
Q2 2020 | $1,928,000 | +46.1% | 91,838 | +60.8% | 0.00% | – |
Q1 2020 | $1,320,000 | +126.0% | 57,118 | +153.4% | 0.00% | – |
Q4 2019 | $584,000 | -17.2% | 22,540 | -37.8% | 0.00% | – |
Q3 2019 | $705,000 | +79.8% | 36,211 | +50.7% | 0.00% | – |
Q2 2019 | $392,000 | -25.6% | 24,030 | +3.3% | 0.00% | – |
Q1 2019 | $527,000 | +7.1% | 23,264 | +21.0% | 0.00% | – |
Q4 2018 | $492,000 | +48.6% | 19,233 | +89.4% | 0.00% | – |
Q3 2018 | $331,000 | -60.5% | 10,156 | -72.5% | 0.00% | – |
Q2 2018 | $838,000 | -3.9% | 36,932 | +2.7% | 0.00% | – |
Q1 2018 | $872,000 | -7.1% | 35,978 | +6.8% | 0.00% | – |
Q4 2017 | $939,000 | -67.2% | 33,683 | -59.7% | 0.00% | – |
Q3 2017 | $2,866,000 | +136.7% | 83,684 | +175.3% | 0.00% | – |
Q2 2017 | $1,211,000 | -58.3% | 30,394 | -61.4% | 0.00% | -100.0% |
Q1 2017 | $2,902,000 | -13.6% | 78,821 | -25.1% | 0.00% | 0.0% |
Q4 2016 | $3,357,000 | -15.7% | 105,300 | -4.2% | 0.00% | 0.0% |
Q3 2016 | $3,982,000 | +41.8% | 109,868 | -11.3% | 0.00% | 0.0% |
Q2 2016 | $2,809,000 | +41.0% | 123,807 | +16.8% | 0.00% | – |
Q1 2016 | $1,992,000 | +5.3% | 106,017 | -8.1% | 0.00% | – |
Q4 2015 | $1,891,000 | +42.4% | 115,392 | -4.5% | 0.00% | – |
Q3 2015 | $1,328,000 | +17.5% | 120,792 | +39.1% | 0.00% | – |
Q2 2015 | $1,130,000 | -20.5% | 86,821 | +5.9% | 0.00% | – |
Q1 2015 | $1,422,000 | -3.0% | 81,990 | -16.5% | 0.00% | -100.0% |
Q4 2014 | $1,466,000 | -53.9% | 98,210 | -28.8% | 0.00% | 0.0% |
Q3 2014 | $3,181,000 | -43.6% | 137,993 | -22.1% | 0.00% | -50.0% |
Q2 2014 | $5,644,000 | – | 177,058 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
King Wealth Management Group | 22,500 | $583,000 | 0.15% |
Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |